Today: 7 February 2026
Subscribe
Browse Category

Biotech Stocks News 18 December 2025 - 22 December 2025

Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

Dec. 22, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” into a deal-driven stock, after BioMarin Pharmaceutical announced an all-cash agreement to acquire Amicus for $14.50 per share. With shares trading around $14.18 on Dec. 22, the market is now pricing FOLD mostly on closing probability and timing, not clinical catalysts. Investing.com+1 That change in narrative is already visible in analyst actions dated 22.12.2025: TD Cowen downgraded Amicus to Hold and reset its target to $14.50, essentially treating the stock as a merger-arbitrage position rather than a standalone biotech. Investing.com Below is the
22 December 2025
······
Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Insmed Incorporated (NASDAQ: INSM) heads into the Monday, Dec. 22, 2025 session with two powerful—almost opposing—forces in play: a fresh clinical disappointment that jolted sentiment last week, and a major index catalyst that can drive mechanical buying at the open. Shares last closed at $174.84 (up about 5% on the day) after an exceptionally volatile week for the biotech, with after-hours trading roughly flat. StockAnalysis Below is what investors and traders typically want on their radar before the bell. The biggest catalyst for Monday: Insmed joins the Nasdaq-100 before the open Insmed is scheduled to be added to the Nasdaq-100
22 December 2025
·····
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely to hinge less on quarterly fundamentals and more on the probability, timing, and conditions of closing. SEC+1 FOLD last traded around $14.18 (near the offer price), reflecting how quickly the market repriced the shares after the announcement. Investors.com Below is the week-ahead playbook: the latest news as of 21.12.2025, what Wall Street is saying, and the specific catalysts that could
22 December 2025
······
Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen Inc. (NASDAQ: BIIB) heads into the Christmas week with its stock hovering just below a recent high, a fresh spike in trading volume, and a narrative that’s increasingly dominated by one question: can the company turn Leqembi’s momentum into a durable growth engine while legacy revenue lines mature and competition intensifies? As of Sunday, December 21, 2025, BIIB is coming off a strong finish to last week—closing Friday, Dec. 19 at $174.80, up 2.88% on the session, with unusually heavy volume for the name. MarketWatch That closing level still sits below the 52-week high of $185.17 (set Nov. 24),
21 December 2025
····
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Insmed Incorporated (NASDAQ: INSM) is heading into a pivotal (and holiday-shortened) trading week with two narratives pulling on sentiment at the same time: That push-pull dynamic is likely to define the week-ahead setup for INSM as markets reopen Monday. INSM stock snapshot heading into the week (as of Dec. 21, 2025) Because this coming week includes Christmas holiday trading conditions, liquidity can be thinner than normal—sometimes amplifying both index-related moves and any lingering “headline drift” from last week’s biotech news. The headline that sparked the volatility: brensocatib CRSsNP Phase 2b miss What happened On
21 December 2025
···
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) has effectively shifted from a “biotech story stock” to a deal-driven stock. The reason is simple and decisive: BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire Amicus in an all-cash transaction priced at $14.50 per share, putting a hard cap on the near-term upside—unless a competing bid emerges. SEC+1 With U.S. markets closed for the weekend, the most recent close available is $14.18 (Dec. 19, 2025)—a roughly 30% one-day jump that pushed shares close to the deal price and turned the remaining gap into a classic merger-arbitrage spread. StockAnalysis Below
21 December 2025
······
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50 per share in cash, a premium of about 33% to Amicus’ prior close. Reuters+2BioMarin Corporate+2 On December 19, FOLD shares surged and closed at $14.18, just below the cash consideration—leaving a small spread that now reflects time to close, regulatory clearance, and deal risk rather than day-to-day biotech sentiment. Finviz+1 Below is a comprehensive roundup of the latest news, forecasts,
20 December 2025
······
Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

As of Saturday, December 20, 2025, investors are digesting a busy stretch of developments around Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)—from Nasdaq-100 index inclusion (effective Dec. 22) to fresh reimbursement tailwinds in the U.K. and continued focus on Amvuttra (vutrisiran) as the company’s main growth engine. Nasdaq+1 Below is a comprehensive roundup of the latest ALNY stock news, forecasts, and market-moving analysis available as of 20.12.2025, plus what to watch next. ALNY stock today: where Alnylam shares stand on Dec. 20, 2025 U.S. markets are closed on Saturday, so the most recent official pricing is from Friday’s session (Dec. 19, 2025).
20 December 2025
·····
Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine, Inc. (NASDAQ: IRON) stock is seeing a classic “biotech catalyst storm” on Dec. 20, 2025: big intraday swings, headline-driven volatility, and analysts arguing over whether the market is repricing risk or merely repricing uncertainty. As of the latest trading data available, IRON was around $80.04, down roughly 11.5% versus the prior close, after trading as high as $94.60 and as low as $71.46 on heavy volume (about 4.22 million shares). The immediate trigger: a report-driven debate about the FDA’s new fast-track voucher process and whether Disc’s lead drug candidate, bitopertin, remains on the clean, accelerated path bulls were
20 December 2025
·····
Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) finished Friday, December 19, 2025, with shares around $400 and little change in after-hours trading — but the setup into the next U.S. session looks more eventful than the calm “after the bell” tape suggests. ALNY ended the day near $400.23 (up about 1.15%), after trading roughly between the mid-$395s and low-$408s on heavy volume (about 12.6 million shares). Investing.com Because December 19 was a Friday, the next U.S. equity market open is Monday, December 22, 2025 — and that date matters for ALNY for one major reason: the Nasdaq-100 index reconstitution takes effect before
20 December 2025
·····
Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight on December 18, 2025—not because of a brand-new press release, but because the stock is still digesting one of the most volatile biotech weeks of the year. In Thursday trading, WVE stock fell roughly mid-single digits, hovering in the mid-$15 range after closing around $16.34 the prior session, according to market data and widely circulated market recaps. StockAnalysis+1 That pullback matters because it comes right after a dramatic early-December surge tied to Wave’s obesity program—and immediately following a large equity financing that materially changes the company’s cash position and
18 December 2025
····
Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch

Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch

December 18, 2025 — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is back in the spotlight after a sharp two-day move that pushed the stock back to the $2.5 area—still far below where many Wall Street price targets sit, but enough to reignite the “is this finally a bottom?” debate around one of biotech’s most volatile commercial launches. According to Investing.com’s recent trading history, IOVA jumped 12% on Wednesday, December 17, closing at $2.52 on 23.27 million shares after already rising on December 16. Investing.com As of December 18, the stock continued to trade around $2.52, with a recent 52-week range of
18 December 2025
·····
1 2 3 4 5 6

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop